5 Top Weekly NASDAQ Biotech Stocks: Molecular Templates on Top

Molecular Templates, Galectin Therapeutic, Chiasma, ZioPharm Oncology and Caladrius Biosciences were last week’s top gainers on the NASDAQ Biotechnology Index.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) had nearly a one percent increase over the past trading week to 3,737.25 points as of 2:30 p.m. EST Friday (September 21).

Company news in the pharmaceutical and biotech sectors led to further highlights for investors. Starting off the week, Argenx (NASDAQ:ARGX) released positive clinical trial data from its proof-of-concept trial for its rare disease drug, efgartigimoid (ARGX-113).

The drug is in development as a treatment for primary immune thrombocytopenia (ITP) in adult patients.

Exelixis (NASDAQ:EXEL) also had positive news sharing its partner Ipsen Biopharmaceuticals (EPA:IPN) received Health Canada approval for a kidney cancer treatment.

Under the terms of an agreement between the two companies, Exelixis will receive US$5 million from Ipsen for the approval within the next 70 days.

Against this news, a number of other NASDAQ biotech stocks saw significant share price increases last week. The five top gainers are as follows:

  • Molecular Templates (NASDAQ:MTEM)
  • Galectin Therapeutic (NASDAQ:GALT)
  • Chiasma (NASDAQ:CHMA)
  • ZioPharm Oncology (NASDAQ:ZIOP)
  • Caladrius Biosciences (NASDAQ:CLBS)

Here’s a closer look at those companies and what moved their share prices last week. Share prices are quoted in US dollars and were taken from Google Finance as of 12:30 p.m. EST on Friday.

Molecular Templates

Leading the top weekly NASDAQ biotech stocks list this week is Molecular Templates with a 38.85 percent increase, pushing the share price to $5.60.

On Wednesday (September 19) the company announced a Big Pharma deal with Takeda Pharmaceutical (TSE:4502) to develop protein-based oncology therapy. The companies will work together to develop a CD38-targeted drug as a treatment for multiple myeloma. This is the same drug candidate the companies developed in a previous discovery-phase partnership.

In addition to this drug in its pipeline, the company is working to develop other next-generation immunotoxins called Engineered Toxin Bodies to treat cancer and other serious diseases.

Galectin Therapeutics

Galectin uses carbohydrate technology to target key proteins in developing treatments for cancer and fibrotic disease. The company’s stock price increased 29.29 percent to $6.52.

In the previous trading week Galectin announced positive preliminary results from GR-MD02 in its Phase 1b trial with Keytruda as a treatment for advanced melanoma, neck and head cancer. The results reported an objective response rate of 50 percent while the response rate of Keytruda alone is 33 percent in melanoma.

Chiasma

Middle of our weekly top NASDAQ biotech stocks list is Chiasma with a share price of $3.19 with a 21.15 percent increase.

This biopharmaceutical company is using its proprietary TPE technology to injections into oral medications. Though the company didn’t have any news released in the past week it did present at the International Congress of the Growth Hormone Research and IGF Societies, in the US on September 16. The presentation highlighted results from the ongoing MPowered Phase 3 trial testing a pill version of an injection for a hormone disorder.

ZioPharm Oncology

Similar to other companies on this list, ZioPharm is an oncology-focused company, in this case it’s directing efforts to develop next-generation immunotherapies using gene and cell-based therapies. The company hasn’t had big news in the past few weeks, however it did announce a new director was added to the board on September 4, 2018.

Nearing the end of the top NASDAQ biotech stocks list, ZioPharm’s share price increased 18.08 percent over the past trading week to $3.07.

Caladrius Bio

The last company to make it on the weekly top NASDAQ biotech stocks list is Caladrius. Similar to ZioPharm, this company didn’t have any news in the past few weeks that may have spurred this share price increase. The most recent news from the company in late-August was an announcement to present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018.

Caladrius’ stock price hit $6.40 with an overall increase of 16.70 percent.

Don’t forget to follow us at @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using Globe and Mail’s Stock Filter. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.


***This article is updated weekly. Scroll to the top for the most accurate information.***

5 Top Weekly NASDAQ Biotech Stocks: Bellerophon Lands on Top

By Gabrielle Lakusta, September 16, 2018

Over the last trading week, the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) decreased slightly by 1 percent to 3,704.4 points as of 12:00 p.m. EST on Friday (September 14).

Last week was filled with exciting milestones and company news investors have showed excitement over. On Wednesday (September 12), Nemaura Medical (NASDAQ:NMRD) announced positive interim data for its continuous glucose monitor, the SugarBEAT.

This news means the company expects to finish the US study and submit applications for approval to the US Food and Drug Administration (FDA) in Q1 2019.

Other big news includes a collaboration between Oncolytics Biotech SOLTI (TSX:ONC,NASDAQ:ONCY) for a Phase 3 clinical trial developing Reolysin (pelareorep) for metastatic breast cancer.

Against that backdrop, a number of other NASDAQ biotech stocks saw significant share price increases last week. The five top gainers are as follows:

  • Bellerophon Therapeutics (NASDAQ:BLPH)
  • Osiris Therapeutics (NASDAQ:OSIR)
  • Biospecifics Technologies (NASDAQ:BSTC)
  • Aevi Genomic Medicine (NASDAQ:GNMX)
  • Curis (NASDAQ:CRIS)

Here’s a closer look at those companies and what moved their share prices last week. Share prices are quoted in US dollars and were taken from Google Finance as of 12:00 p.m. EST on Friday.

Bellerophon

Bellerophon is first on our top weekly NASDAQ biotech stocks with a share price increase of 46.74 percent over last week’s trading period to reach $1.25.

While the company didn’t have any news last week, it did present at the Rodman & Renshaw Annual Global Investment Conference on September 5, which may have carried its share price movement.

The company specializes in biotherapeutics and is developing products to treat cardiopulmonary and cardiac diseases. In its pipeline are three product candidates featuring the company’s INOpulse technology. One is a treatment for pulmonary arterial hypertension, and the other two are for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease and pulmonary hypertension associated with interstitial lung disease.

Osiris Therapeutics

Osiris is developing regenerative medicine products to improve patient healthcare outcomes and costs. The company is known for its Grafix line of products in orthopedics, sports medicine and wound care. Over the past trading week Osiris’ share price increased 35.85 percent to $11.54.

Although the company didn’t have any news in the previous week it did have a big announcement in early August that the company would re-list on the NASDAQ global market. In late August, Osiris announced a peer-reviewed publication which had positive results for its Grafix patients treating chronic diabetic foot ulcers.

Biospecifics Technologies

Middle of the pack on our weekly NASDAQ biotech stocks list is Biospecifics Tech, which is developing collagenase-based therapies. The company’s collagenase-based product Xiaflex is marketed in the US and in Europe under the name Xiapex.

Similar to other companies on the list this week, Biospecifics didn’t have any news in the past week, however it present at two conferences on September 6 and 7. One was an investor specific conference, whereas the other was a biotech industry conference. Biospecifics share price increased 21.05 percent to $60.11.

Aevi Genomic Medicine

Aevi didn’t have any news in last week’s trading period, although it most recently presented at the H.C. Wainwright Global Investment Conference in early September. Over the five-day trading period, shares of the company increased 12.16 percent to $1.28.

The company’s focus is on working with genomic medicine to translate genetic discoveries into novel therapies, such as with AEVI-001. Aside from this trial, the company is also working on treatments for Crohn’s disease and another undisclosed rare pediatric disease.

Curis

With a 8.84 percent share price increase to $1.60, Curis lands last on our weekly top NASDAQ biotech stocks.

Like other companies on our list, the company’s most recent news was it presenting at a conference in early September. Curis presented at the Baird 2018 Global Healthcare Conference.

Curis is a biotech developing treatments for cancers, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. The company receives royalty income from the approved product, Erivedge, which was developed and marketed to Genentech.

Don’t forget to follow us at @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using Globe and Mail’s Stock Filter. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

Featured
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

read more Show less
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuitsBristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019Lead Plaintiff Motion ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits

Bristol-Myers Squibb Company (NYSE:BMY)

read more Show less
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion Deadline: December 6, 2021 MISLEADING ...

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

read more Show less
text saying "top stories this week"

Catch up and get informed with this week's content highlights from Charlotte McLeod, our editorial director.

Top Stories This Week: Powell Gets Fed Nomination, Using Gold in a Market Correction youtu.be

We're back after a break last week with quite a bit to cover in the gold space.

After running up past the US$1,860 per ounce mark midway through November, the yellow metal has taken a tumble. At the time of this writing on Friday (November 26) afternoon, it was sitting just under US$1,790.

Gold's losses this week have been attributed to elements like a stronger US dollar and better Treasury yields, although Jerome Powell's US Federal Reserve chair renomination has pulled other factors into play — some market watchers believe he may move to taper and raise interest rates faster than anticipated.


If the Fed follows its previously laid out timeline for tapering, it will wrap up in mid-2022; the central bank has said it won't raise rates until after that. It has also emphasized that its roadmap may change if necessary.

Looking at the larger picture for gold, I heard recently from Nick Barisheff of BMG Group, who believes the stock market is due for a major correction.

"The market is due for a major correction. What will cause it and when it will happen is anybody's guess — it could be tomorrow, it could be six months from now" — Nick Barisheff, BMG Group

It's impossible to know when this correction will happen, but Nick emphasized the importance of acting before it's too late. He pointed out that investors are typically slow to get out of the market once a crash actually begins — they wait for a turnaround, and by the time it's clear there won't be one, they've experienced big losses.

In his opinion, the solution is to get out of the stock market early and transfer money into gold.

Here's how Nick explained it:

"Instead of taking your money off the table and going into cash … you go to gold (because cash is devaluing daily). Gold will at least hold its own and probably appreciate … so by sitting it out in gold you can wait until the market finishes correcting and then buy back in" — Nick Barisheff, BMG Group

With gold's future in mind, we asked our Twitter followers this week what price they think the metal will be at the end of 2021. By the time the poll closed, most respondents had voted for the US$1,800 to US$1,900 range.

We'll be asking another question on Twitter next week, so make sure to follow us @INN_Resource or follow me @Charlotte_McL to share your thoughts.

Finally, in the cannabis space, INN's Bryan Mc Govern spoke with Dan Ahrens of AdvisorShares to get his thoughts on 2021 trends and what's ahead in 2022.

Dan was candid, and said if he had to choose one word to describe the cannabis market in 2021, it would be "painful." Like many others, he's been disappointed in the industry's performance — while positivity initially ran high due to excitement about potential federal changes in the US, ultimately progress has been slow.

"Cannabis started with a big run-up in January and February ... and things dragged from there" — Dan Ahrens, AdvisorShares

Still, Dan has hope for 2022 and said it will be a "huge year" for cannabis. He believes US reforms will come sooner rather than later, and in his opinion those widely anticipated changes will bring a wave of M&A activity.

Specifically, he expects to see alcohol, tobacco and other consumer packaged goods companies making deals with cannabis players, not just cannabis entities doing transactions with each other.

"Those big alcohol companies, tobacco companies, other consumer packaged goods product companies — they're waiting. They're waiting on the US" — Dan Ahrens, AdvisorShares

Want more YouTube content? Check out our YouTube playlist At Home With INN, which features interviews with experts in the resource space. If there's someone you'd like to see us interview, please send an email to cmcleod@investingnews.com.

And don't forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

cannabis plant layered with German flag graphic
Dmytro Tyshchenko / Shutterstock

Catch up on some of the biggest news of the week for the cannabis investment world.

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.


Coalition of parties promises forward-looking cannabis policy

Germany, a country with comprehensive and elaborate medicinal rules for cannabis, is in a time of transition as a new government is set to begin to take over after 16 years of Angela Merkel.

Olaf Scholz, the proposed next chancellor of Germany, leads a three party coalition that will become the country's governing body. As part of its promises, talk of adult-use cannabis regulation has now gained even more momentum. A report from MJBizDaily quotes a German policy document that shows the coalition's stance:

"We are introducing the controlled distribution of cannabis to adults for consumption purposes in licensed shops. This controls the quality, prevents the transfer of contaminated substances and guarantees the protection of minors."

However, despite the promise and excitement, it remains to be seen how these ideas will be applied since no formal regulations have been drafted or approved yet.

Canadian cannabis retailer partners with popular delivery app

Tokyo Smoke, a cannabis retail operator in Canada owned by Canopy Growth (NASDAQ:CGC,TSX:WEED), announced a collaboration agreement with Uber Canada (NYSE:UBER) whereby cannabis consumers will be able to use the Uber Eats app to order products before they visit stores.

While the app won't let consumers get cannabis delivered to them, this new method opens the doors to more dynamic ways of buying cannabis.

"As a market leader in innovation and a platform used by so many Canadians, we believe this is the ideal next offering that can be done safely and conveniently on the Uber Eats app," Mark Hillard, vice president of operations with Tokyo Smoke, said in a press release.

A report from the Canadian Press indicates Ontario is considering allowing dispensaries to have delivery and pickup options made available to consumers permanently. The province allowed some of these purchasing options at the outset of the COVID-19 pandemic, but then removed them.

Lola Kassim, general manager of Uber Eats Canada, said this new end-to-end experience will provide consumers with responsible access to legal cannabis products.

Cannabis company news

  • Organigram Holdings (NASDAQ:OGI,TSX:OGI) issued financial results for its Q4 2021 period. In its report, the company notes a net loss of C$26 million despite a 22 percent uptick in net revenue to C$24.9 million. Beena Goldenberg, the newly appointed CEO of the firm, is encouraged by the market share position earned by the company, which said it became the fourth biggest producer in Canada during the reporting period.
  • Halo Collective (NEO:HALO,OTCQB:HCANF) confirmed the decision for Akanda, its spinoff company focused on international cannabis opportunities, to begin trading on a US exchange. "The number of shares to be offered and the price range for the proposed offering have not yet been determined," the company told investors in a press release.
  • High Tide (NASDAQ:HITI,TSXV:HITI) announced the acquisition of 80 percent of NuLeaf Naturals, a CBD product wellness developer, for an estimated US$31.24 million. The deal includes a three year option clause for High Tide to complete a total acquisition. "As international markets open up and as export regulations evolve, NuLeaf's cGMP-certified facility positions us to take advantage of the global CBD business opportunity," Raj Grover, president and CEO of High Tide, said.
  • Humble & Fume (CSE:HMBL,OTC Pink:HUMBF) released the financial report for its first 2022 fiscal quarter to shareholders and the market. "As the legal cannabis market in North America continues to mature, Humble remains agile and focused on providing a leading solution for brands to scale quickly and retailers to focus on their customers," Joel Toguri, CEO of Humble, said.

Don't forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

MARKETS

Markets
TSX21125.90-487.28
TSXV944.05-31.53
DOW34899.34-905.04
S&P 5004594.62-106.84
NASD15491.66-353.57
ASX7279.30-128.00

COMMODITIES

Commodities
Gold1792.60+0.99
Silver23.13+0.02
Copper4.29-0.18
Palladium1751.49+10.50
Platinum955.50+2.50
Oil68.17-10.22
Heating Oil2.09-0.29
Natural Gas5.49+0.43

DOWNLOAD FREE REPORTS